EXINI

Lund October 16, 2014

EXINI to arrange Bone Scan Index (BSI) symposium at important annual European congress

EXINI and FUJIFILM RI Pharma will arrange a Bone Scan Index (BSI) symposium on October 20th at this year's EANM-congress (European Association of Nuclear Medicine) held in Gothenburg, October 18-22.

The symposium called *"Bone Scan Index (BSI) A Nuclear Medicine Biomarker in Metastatic Prostate Cancer"*, commence at 13.00 p.m. **For more information >> Program**

"The symposium provide a unique opportunity for invited physicians within nuclear medicine, to learn more about the imaging biomarker BSI and its clinical applications. Arranging it together with our partner FUJIFILM RI Pharma adds extensive clinical experience and insights gained from the success of our product EXINI bone^{BSI} (Bonenavi) on the Japanese market ", comments Magnus Aurell, CEO, EXINI Diagnostics AB.

Throughout the congress, several academic studies based upon use of the software EXINI bone^{BSI} and its BSI-calculating capacity, will be presented:

OP365: *Prognostic value of bone scan index for treatment response and survival in patients with high-risk prostate cancer. M. Reza, A. Bjartell, M. Ohlsson, R. Kaboteh, P. Wollmer, L. Edenbrandt, E. Trägårdh*

P491: *Analytical validation of automated bone scan index as a candidate imaging biomarker for advanced prostate cancer. A. Anand, L. Edenbrandt, A. Bjartell, D. Minarik*

P502: *Reproducibility of automated bone scan index in patients with advanced prostate cancer. A. Anand, L. Båth, R Kaboteh, A. Bjartell, L. Edenbrandt*

P786: *Routine usefulness analysis of computer assisted diagnosis (CAD) software for bone scan index.L. Ferrer, M Colombie, D. Rusu, D. Goulon, B. Jamet, N. Varmenot, F. Kraeber-Bodere, C. Rousseau*

More on Bone Scan Index (BSI):
BSI is an imaging biomarker providing fast, accurate and quantifiable information to be used for diagnosis and stratification and the monitoring of treatment response. It also provides increased accuracy in prognoses involving patients suffering from skeletal metastases originating from prostate- or breast cancer.

What is more, BSI has demonstrated its importance in the process of developing new drugs, thus proving itself just as important for clinical use as for the pharmaceutical industry. EXINI bone^{BSI} is the only software capable of extracting BSI-values for both these purposes.

www.bonescanindex.org
www.exini.com/software-bone-bsi/

For more information, please contact:
Magnus Aurell, CEO
Phone: +46 46-286 54 25
E-mail: magnus.aurell@exini.com